Veoza (fezolinetant) - Risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment

13/01/2025
Medicines for human use Direct healthcare professional communication (DHPC)

Important Safety Information from Astellas Pharma Europe regarding Veoza (fezolinetant): Risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment

Documents

Veoza (fezolinetant) - Direct Healthcare Professional Communication January 2025 PDF : 387KB | 16/01/2025